Mayo Alzheimer's Disease Research Center

描述（由申请人提供）：第一个国家计划，以解决阿尔茨海默病是在2012年5月发布，并为阿尔茨海默病（AD）的研究设定了蓝图，以实现有效治疗和预防疾病的目标，到2025年。为了实现这一目标，马约阿尔茨海默病研究中心（ADRC）正在进行研究，以实现这一目标。该中心将由五个核心组成：行政核心，负责监督中心的运作;临床核心，负责招募和描述AD谱和AD相关痴呆症的受试者;数据管理和统计核心，负责收集、完善和分析数据，并符合国家阿尔茨海默病协调中心的要求;神经病理学核心对尸检标本进行详细的神经病理学研究，并向合作者传播遗传标本和其他生物标本;外联、招募和教育核心协助招募和鉴定研究对象。ADRC还提出了三个新的研究项目，其中一个由一名初级研究人员进行。项目1，“使用成像改善痴呆病理学和长期结局的临床预测”，Prashanthi Vemuri博士，将开发一种使用临床和成像数据来预测痴呆亚型的软件方法;项目2，“验证HDAC 6作为阿尔茨海默病Tauopathy的新型治疗靶点”，主要研究者伦纳德Petrucelli博士，将验证细胞溶质组蛋白脱乙酰酶6的抑制 其调节过度磷酸化的tau的积累作为治疗AD的可能策略;项目3，“ApoE同种型在脑血管和CAA中”，Goujun Bu，Ph.D.，将研究ApoE和ApoE受体在AD发病机制中的作用。ADRC将继续保持一个活跃的研究受试者队列，并将招募一个新的风险队列。 路易体障碍的受试者。该中心将继续作为马约诊所的AD研究中心，并将与全国各地的国家老龄化研究所和其他阿尔茨海默病中心进行互动。随着AD和相关痴呆症研究领域的进展，该中心将保持灵活性并适应新的方向。

DESCRIPTION (provided by applicant): The First National Plan to Address Alzheimer's Disease was released in May of 2012 and set a blueprint for research in Alzheimer's disease (AD) to achieve the goal of effective treatment and prevention of the disease by 2025. Toward that goal, the Mayo Alzheimer's Disease Research Center (ADRC) is pursuing research to accomplish that goal. The Center will be comprised of five cores: Administrative Core to oversee the operations of the Center; Clinical Core to recruit and characterize subjects along the AD spectrum and for the AD-related dementias; Data Management and Statistical Core to collect, refine and analyze data and be compliant with the requirements of the National Alzheimer's Coordinating Center; Neuropathology Core to perform detailed neuropathological studies on autopsy specimens and disseminate genetic and other biospecimens to collaborators; Outreach, Recruitment and Education Core to assist in the recruitment and characterization of subjects for research purposes. The ADRC is also proposing three new research projects including one by a junior investigator. Project 1, "Improving Clinical Prediction of Dementia Pathology and Long-Term Outcomes Using Imaging," by Prashanthi Vemuri, Ph.D., will develop a software methodology using clinical and imaging data to predict dementia subtypes; Project 2, "Validating HDAC6 as a Novel Therapeutic Target for Alzheimer's Tauopathy," principal investigator Leonard Petrucelli, Ph.D., will validate inhibition of cytosolic histone deacetylase 6 that modulates the accumulation of hyperphosphorylated tau as a possible strategy for the treatment of AD; Project 3, "ApoE Isoforms in Brain Vasculature and CAA," Goujun Bu, Ph.D., will investigate the roles of ApoE and ApoE receptors in the pathogenesis of AD. The ADRC will continue to maintain an active cohort of research subjects and will recruit a new cohort of at-risk subjects for Lewy body disorders. The Center will continue to serve as the nidus for AD research at the Mayo Clinic and will interact with the National Institute on Aging and other Alzheimer's Disease Centers around the country. The Center will remain flexible and adapt to new directions as the field of AD and related dementia research progresses.